These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11165950)

  • 1. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
    Zegels B; Eastell R; Russell RG; Ethgen D; Roumagnac I; Collette J; Reginster JY
    Bone; 2001 Jan; 28(1):108-12. PubMed ID: 11165950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
    Clemmesen B; Ravn P; Zegels B; Taquet AN; Christiansen C; Reginster JY
    Osteoporos Int; 1997; 7(5):488-95. PubMed ID: 9425508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risedronate once a week.
    White NJ; Perry CM
    Treat Endocrinol; 2003; 2(6):415-20; discussion 421. PubMed ID: 15981945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
    Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
    Harris ST; Watts NB; Li Z; Chines AA; Hanley DA; Brown JP
    Curr Med Res Opin; 2004 May; 20(5):757-64. PubMed ID: 15140343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.
    Brown JP; Hosking DJ; Ste-Marie L; Johnston CC; Reginster J; Ryan WG; Johnson TD; Bekker PJ
    Calcif Tissue Int; 1999 Feb; 64(2):93-9. PubMed ID: 9914313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
    Dunn CJ; Goa KL
    Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
    Reginster J; Minne HW; Sorensen OH; Hooper M; Roux C; Brandi ML; Lund B; Ethgen D; Pack S; Roumagnac I; Eastell R
    Osteoporos Int; 2000; 11(1):83-91. PubMed ID: 10663363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
    Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
    Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of risedronate in postmenopausal women intolerant of alendronate.
    Adachi JD; Adami S; Miller PD; Olszynski WP; Kendler DL; Silverman SL; Licata AA; Li Z; Gomez-Panzani E
    Aging (Milano); 2001 Oct; 13(5):347-54. PubMed ID: 11820707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
    Shiraki M; Fukunaga M; Kushida K; Kishimoto H; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H
    Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
    Watts NB; Lindsay R; Li Z; Kasibhatla C; Brown J
    Osteoporos Int; 2003 Jun; 14(5):437-41. PubMed ID: 12730756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.
    Eriksen EF; Melsen F; Sod E; Barton I; Chines A
    Bone; 2002 Nov; 31(5):620-5. PubMed ID: 12477578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of risedronate in the treatment of osteoporosis.
    Geusens P; McClung M
    Expert Opin Pharmacother; 2001 Dec; 2(12):2011-25. PubMed ID: 11825332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
    Li M; Mosekilde L; Søgaard CH; Thomsen JS; Wronski TJ
    Bone; 1995 Jun; 16(6):629-35. PubMed ID: 7669439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
    Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
    Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
    Reid DM; Adami S; Devogelaer JP; Chines AA
    Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.